Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.75 USD | -1.69% | -6.42% | -85.02% |
May. 09 | EFFECTOR Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 04 | Health Care Down on Retreat From Risk -- Health Care Roundup | DJ |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 8.37M |
---|---|---|---|---|---|
Net income 2024 * | -34M | Net income 2025 * | -37M | EV / Sales 2024 * | - |
Net cash position 2024 * | 18M | Net cash position 2025 * | 51M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-0.28
x | P/E ratio 2025 * |
-0.78
x | Employees | 14 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.84% |
Latest transcript on eFFECTOR Therapeutics, Inc.
1 day | -1.69% | ||
1 week | -6.42% | ||
Current month | -22.22% | ||
1 month | -7.41% | ||
3 months | -86.68% | ||
6 months | -87.79% | ||
Current year | -85.02% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Worland
CEO | Chief Executive Officer | 66 | 12-04-30 |
Michael Byrnes
DFI | Director of Finance/CFO | 47 | 20-11-30 |
Douglas Warner
CTO | Chief Tech/Sci/R&D Officer | 52 | 22-08-07 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Worland
CEO | Chief Executive Officer | 66 | 12-04-30 |
Director/Board Member | 54 | 21-08-24 | |
Caroline Loewy
BRD | Director/Board Member | 58 | 23-09-10 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-28 | 1.75 | -1.69% | 66,179 |
24-05-24 | 1.78 | -2.20% | 52,455 |
24-05-23 | 1.82 | +3.41% | 83,519 |
24-05-22 | 1.76 | -1.68% | 69,456 |
24-05-21 | 1.79 | -4.28% | 95,000 |
Delayed Quote Nasdaq, May 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-85.02% | 8.37M | |
+9.83% | 118B | |
+10.80% | 106B | |
-10.84% | 23.4B | |
-1.69% | 22.1B | |
-10.23% | 18.34B | |
-41.92% | 16.59B | |
-15.11% | 15.97B | |
+6.62% | 14.03B | |
+17.53% | 11.67B |
- Stock Market
- Equities
- EFTR Stock